<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-pynnacle-phase-2-trial-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T15:30:00.000Z</news:publication_date>
      <news:title>PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CVS/cvs-home-team-heroes-soccer-contest-winners</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:40:00.000Z</news:publication_date>
      <news:title>CVS Pharmacy® names Grand Prize winners of first Home Team Heroes youth soccer contest</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IMCC/im-cannabis-new-ceo-ronen-zalayet</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:19:00.000Z</news:publication_date>
      <news:title>IM Cannabis Corp. Appoints New CEO to Lead Technology-Driven Business Expansion</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PPBT/purple-biotech-im1240-eortc-nci-aacr-symposium</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:00:00.000Z</news:publication_date>
      <news:title>Purple Biotech&apos;s IM1240, a CAPTN-3-Capped Tri-Specific T- and NK-Cell Engager Targeting 5T4, Shows Robust Tumor Killing in Immunotherapy-Resistant Cancer Models in Plenary Oral Presentation at EORTC-NCI-AACR Symposium</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/JAGX/jaguar-health-reverse-stock-split-november-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:00:00.000Z</news:publication_date>
      <news:title>Jaguar Health, Inc. Announces Reverse Stock Split</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GEHC/ge-healthcare-imaging-360-ai-features</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:00:00.000Z</news:publication_date>
      <news:title>GE HealthCare introduces new Imaging 360 features to simplify protocol management and support radiology workflows</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-phase-1-results-apr-1051</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T14:00:00.000Z</news:publication_date>
      <news:title>Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NVNO/envveno-medical-three-year-data-veith-symposium</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:41:00.000Z</news:publication_date>
      <news:title>enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BTCY/biotricity-reports-q2-fiscal-2027-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:35:00.000Z</news:publication_date>
      <news:title>Biotricity Reports Second Quarter Fiscal 2027 Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SVRA/savara-fda-molgramostim-bla-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:30:00.000Z</news:publication_date>
      <news:title>Savara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-blood-test-cte-study</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:30:00.000Z</news:publication_date>
      <news:title>JAMA Study Using Alamar Biosciences’ NULISA Assay Links Blood eMTBR-tau to Tau tangle Burden in Former Football Players with Advanced CTE</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PLYX/polaryx-therapeutics-ncl-conference-ntsad-event</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:30:00.000Z</news:publication_date>
      <news:title>Polaryx Therapeutics Highlights Participation in NCL Scientific Conference and NTSAD Imagine &amp; Believe Event</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NCNA/nucana-nuc-7738-carfilzomib-multiple-myeloma</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:47.000Z</news:publication_date>
      <news:title>NuCana Presents Preclinical Data Showing NUC-7738 Enhances Carfilzomib Activity in Multiple Myeloma Cell Lines at the 38th EORTC-NCI-AACR Symposium</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALNY/alnylam-webcast-presentations-december-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>Alnylam to Webcast Presentations at Upcoming December Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CVM/celsci-multikine-nadr-designation-saudi-fda</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>CEL-SCI’s Multikine® Receives Saudi FDA NADR Designation, Accelerating Potential Commercial Launch</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ABBV/abbvie-piper-sandler-healthcare-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CTSO/cytosorbents-announces-625-million-financing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>CytoSorbents Announces $6.25 Million Common Stock Financing Priced At-the-Market under Nasdaq Rules and Concurrent Restructuring of Avenue Capital Credit Facility</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BLTE/belite-bio-fda-review-timeline-extension-tinlarebant</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>Belite Bio Announces Extension of FDA Review Timeline for Tinlarebant NDA</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IMDX/imdex-graftassure-galactic-registry-study-launch</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>iMDx Expands GraftAssure Utilization as First Patient Samples Arrive for GALACTIC Registry Study</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ANVS/annovis-fda-agreement-safety-plan-buntanetap-nda</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>Annovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDA</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-ash-2026-events</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>Allogene Therapeutics to Host Events at American Society of Hematology Annual Meeting 2026 Highlighting the Potential of Allogeneic CAR T to Expand Patient Access</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/JNJ/tremfya-guselkumab-phase-4-results-psoriatic-arthritis</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T13:00:00.000Z</news:publication_date>
      <news:title>Late-breaking Johnson &amp; Johnson data in psoriatic arthritis (PsA) shows TREMFYA® (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DHR/danaher-microsoft-smart-scientific-instruments</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T12:30:00.000Z</news:publication_date>
      <news:title>Danaher Collaborates with Microsoft to Make Scientific Instruments Agentically Connected and Laboratories More Intelligent</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DRIO/dario-ceo-erez-raphael-panel-us-bancorp-forum</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T12:30:00.000Z</news:publication_date>
      <news:title>Dario CEO Erez Raphael to Lead Panel Discussion at U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HSCS/heartsciences-shareholders-approve-business-combination</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T12:30:00.000Z</news:publication_date>
      <news:title>HeartSciences Shareholders Approve Proposed Business Combination with Fortitude Mining</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HLF/herbalife-cfo-fireside-chat-bofa-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T12:05:00.000Z</news:publication_date>
      <news:title>Herbalife CFO to Participate in Fireside Chat at Bank of America Leveraged Finance Conference on December 1</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DTIL/precision-biosciences-announces-grant-inducement-awards-nasdaq-listing-rule-5635</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T12:01:00.000Z</news:publication_date>
      <news:title>Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/UTHR/first-transplant-extend-clinical-trial-uthymokidney</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T12:00:00.000Z</news:publication_date>
      <news:title>United Therapeutics Corporation Announces First Transplant in EXTEND Clinical Trial of UThymoKidney™ in Patients with End-Stage Renal Disease</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261120</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T12:00:00.000Z</news:publication_date>
      <news:title>Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ERAS/erasca-phase-1-data-eras-0015</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T12:00:00.000Z</news:publication_date>
      <news:title>Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MRK/merck-trofuse-015-trial-sacituzumab-tirumotecan-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T11:45:00.000Z</news:publication_date>
      <news:title>Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ADXN/addex-therapeutics-q3-2026-financial-results-call</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T06:00:00.000Z</news:publication_date>
      <news:title>ADDEX THERAPEUTICS TO REPORT 2026 THIRD QUARTER FINANCIAL RESULTS AND HOST CONFERENCE CALL ON NOVEMBER 25, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BSX/boston-scientific-prices-3-billion-senior-notes</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T01:45:00.000Z</news:publication_date>
      <news:title>Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ILMN/illumina-wins-virtual-cell-challenge</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20T01:00:00.000Z</news:publication_date>
      <news:title>Illumina Wins Virtual Cell Challenge, Powered by Billion Cell Atlas</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MESO/mesoblast-deloitte-tech-fast-50-award</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T23:51:00.000Z</news:publication_date>
      <news:title>Mesoblast Wins Deloitte Tech Fast 50 Leadership &amp; Enterprise Growth Award</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RVMD/revolution-medicines-phase-1-2-data-rasonque</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T23:05:00.000Z</news:publication_date>
      <news:title>Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CODX/co-diagnostics-reverse-stock-split-november-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T22:00:00.000Z</news:publication_date>
      <news:title>Co-Diagnostics Announces Reverse Stock Split</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GH/guardant-reveal-ultra-launch-mrd-testing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:42:00.000Z</news:publication_date>
      <news:title>Guardant Health Launches Guardant Reveal® Ultra to Deliver Leading Sensitivity in MRD Testing</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HYPR/hyperfine-presents-piper-sandler-healthcare-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:30:00.000Z</news:publication_date>
      <news:title>Hyperfine to Present at the Piper Sandler 38th Annual Healthcare Conference on December 3</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EXOZ/exozymes-third-quarter-2026-results-business-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:25:00.000Z</news:publication_date>
      <news:title>eXoZymes Reports Third Quarter 2026 Results and Provides Business Update at 5PM ET Today</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BLCO/bausch-lomb-phase-2-bl1332-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:15:00.000Z</news:publication_date>
      <news:title>Bausch + Lomb Reports Phase 2 Findings for BL1332 in Post-Surgical Ocular Pain</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-corporate-update-call-november-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:15:00.000Z</news:publication_date>
      <news:title>Summit Therapeutics to Host Corporate Update and Operational Progress Call on November 30, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MEDS/datameds-ai-acquires-tbia-cancer-ai-platform</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:11:00.000Z</news:publication_date>
      <news:title>DataMEDS AI Agrees to Acquire TBIA Cancer AI Blood Test Platform From Todos Medical Estate for Subsidiary Helomics, Inc.</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AZR/azora-therapeutics-inducement-grant-nasdaq-rule-5635</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:10:00.000Z</news:publication_date>
      <news:title>Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SIBN/si-bone-piper-sandler-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:09:00.000Z</news:publication_date>
      <news:title>SI-BONE To Present at Piper Sandler 38th Annual Healthcare Conference on December 1, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BIIB/biogen-participate-december-healthcare-conferences</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:06:00.000Z</news:publication_date>
      <news:title>Biogen to Participate in December Healthcare Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-piper-sandler-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:05:00.000Z</news:publication_date>
      <news:title>Pulse Biosciences to Present at Piper Sandler 38th Annual Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LAB/standard-biotech-merger-treeline-biosciences-approval</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:05:00.000Z</news:publication_date>
      <news:title>Standard BioTools Stockholders Approve All Proposals Related to Merger with Treeline Biosciences and Sale of Mass Cytometry Business</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261119</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:05:00.000Z</news:publication_date>
      <news:title>Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RXST/rxsight-presents-piper-sandler-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:05:00.000Z</news:publication_date>
      <news:title>RxSight, Inc. to Present at the Piper Sandler Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CLDX/celldex-phase-2-barzolvolimab-atopic-dermatitis-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:01:00.000Z</news:publication_date>
      <news:title>Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/KMDA/kamada-tax-ruling-dividend-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:01:00.000Z</news:publication_date>
      <news:title>Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DRTS/alpha-tau-q3-2026-results-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T21:00:00.000Z</news:publication_date>
      <news:title>Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NTHI/neonc-fda-rescheduled-neo212-meeting-november-23</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T18:38:13.000Z</news:publication_date>
      <news:title>NeOnc Technologies Announces FDA Rescheduled NEO212 End-of-Phase 1 Type B Meeting to November 23</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BIIB/lecanemab-clarity-ad-csf-substudy-findings-ctad-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T18:35:27.000Z</news:publication_date>
      <news:title>Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HLF/herbalife-launches-fuel-her-power-nutrition-guide</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T18:31:00.000Z</news:publication_date>
      <news:title>Herbalife Launches Fuel Her Power, a Nutrition Guide for Active Women</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/COSM/cosmos-health-resume-share-repurchases-lock-up</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T15:30:00.000Z</news:publication_date>
      <news:title>Cosmos Health to Resume Share Repurchases as Insiders Commit to 12-Month Lock-Up</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BDX/bd-85-years-medical-device-manufacturing-glens-falls</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:30:00.000Z</news:publication_date>
      <news:title>BD Marks 85 Years of Essential Medical Device Manufacturing in Glen Falls, NY</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CING/cingulate-ct-2103-patent-issuance</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:29:00.000Z</news:publication_date>
      <news:title>Cingulate Announces U.S. Patent Issuance for CTx-2103, Further Validating PTR™ Technology Platform</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NXGL/nexgel-postpones-q3-2026-conference-call</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:25:00.000Z</news:publication_date>
      <news:title>NEXGEL Postpones Third Quarter 2026 Financial Results and Corporate Update Conference Call to November 24th</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HALO/halozyme-update-german-injunction-hearing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:20:00.000Z</news:publication_date>
      <news:title>Halozyme Provides Update on German Preliminary Injunction Hearing</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-reverse-stock-split-november-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:09:00.000Z</news:publication_date>
      <news:title>Lisata Therapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LEXX/lexaria-human-study-glp-1-h26-7-completes-dosing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:05:33.000Z</news:publication_date>
      <news:title>Lexaria’s Human Study GLP-1-H26-7 Completes Dosing as Scheduled</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PHG/philips-advanced-image-insights-ai-orchestration</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:00:00.000Z</news:publication_date>
      <news:title>Philips introduces Advanced Image Insights for advanced visualization and AI orchestration</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ABT/abbott-voyager-trial-encantor-tavi-system</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:00:00.000Z</news:publication_date>
      <news:title>Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosis</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MODD/modular-medical-secures-pbm-coverage-agreements</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T14:00:00.000Z</news:publication_date>
      <news:title>Modular Medical Secures Coverage Agreements with All Three of the Nation&apos;s Largest PBMs for Pivot Insulin Delivery System</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/JNJ/johnson-johnson-ottava-robotic-surgical-system-installation</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:51:00.000Z</news:publication_date>
      <news:title>Johnson &amp; Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health System</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-canadian-patent-ovarian-cancer-vaccine</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:45:00.000Z</news:publication_date>
      <news:title>Anixa Biosciences Announces Issuance of Canadian Patent Strengthening International Protection for its Ovarian Cancer Vaccine Technology</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SSII/ss-innovations-dual-console-beating-heart-tecab-surgery</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:30:00.000Z</news:publication_date>
      <news:title>SS Innovations Announces World’s First Dual-Console, Beating-Heart TECAB Surgery Utilizing All Five Arms of the SSi Mantra Surgical Robotic System</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MSA/msa-safety-welcomes-stanley-elliott-vp-investor-relations</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:30:00.000Z</news:publication_date>
      <news:title>MSA Safety Welcomes Stanley Elliott as Vice President, Investor Relations</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/VOGX/vogenx-joins-russell-indexes</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:30:00.000Z</news:publication_date>
      <news:title>Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HCA/hca-healthcare-crush-the-crisis-2023</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:30:00.000Z</news:publication_date>
      <news:title>HCA Healthcare Collects Record-Breaking 21,857 Pounds of Medication During Eighth Annual “Crush the Crisis”</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IBRX/immunitybio-fastest-growing-technology-company</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:30:00.000Z</news:publication_date>
      <news:title>ImmunityBio Named No. 2 Fastest-Growing Technology Company in North America on the 2026 Deloitte Technology Fast 500™</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CNXU/conexeu-sciences-appoints-daniel-bradbury-chairman</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:30:00.000Z</news:publication_date>
      <news:title>Conexeu Sciences Appoints Life Sciences Veteran Daniel M. Bradbury as Chairman of the Board of Directors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ICUI/icu-medical-piper-sandler-healthcare-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:30:00.000Z</news:publication_date>
      <news:title>ICU Medical to Participate at the Piper Sandler 38th Annual Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RNXT/renovorx-appoints-richard-stark-board-directors</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:30:00.000Z</news:publication_date>
      <news:title>RenovoRx Appoints Interventional Oncology Medtech Leader Richard Stark to its Board of Directors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BHC/bausch-health-solta-medical-10-million-treatments</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:09:07.466Z</news:publication_date>
      <news:title>Bausch Health&apos;s Aesthetic Business, Solta Medical, Surpasses 10 Million Treatments Worldwide</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-participate-upcoming-investor-conferences</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:05:00.000Z</news:publication_date>
      <news:title>Harmony Biosciences to Participate in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/VIVS/vivosim-labs-seven-figure-agreement-pharma-company</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:05:00.000Z</news:publication_date>
      <news:title>VivoSim Labs Signs Seven-Figure Agreement with a Top-10 Global Pharmaceutical Company; Expects to Exceed Its 500%+ Revenue Growth Guidance for Fiscal 2027</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/JNJ/jnj-caplyta-fda-approval-bipolar-mania</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:01:00.000Z</news:publication_date>
      <news:title>Johnson &amp; Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/APMD/national-survey-people-sleep-apnea-treatment</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:00:38.000Z</news:publication_date>
      <news:title>New National Survey Found Many People With Sleep Apnea Struggle to Stay on Treatment</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GEHC/ge-healthcare-mangaciclanol-phase-3-trial</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:00:00.000Z</news:publication_date>
      <news:title>GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HUMA/humacyte-sbla-hemodialysis-access-atev</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:00:00.000Z</news:publication_date>
      <news:title>Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-gerd-awareness-week-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:00:00.000Z</news:publication_date>
      <news:title>Phathom Pharmaceuticals Marks GERD Awareness Week 2026 by Urging Americans to Take Frequent Heartburn Seriously</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IRLA/irulya-therapeutics-evercore-healthcare-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:00:00.000Z</news:publication_date>
      <news:title>IRulya Therapeutics to Participate in the 9th Annual Evercore Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALT/altimmune-participate-evercore-healthcare-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:00:00.000Z</news:publication_date>
      <news:title>Altimmune to Participate in the 9th Annual Evercore Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TVRD/tvardi-advances-tti-109-ind-in-ibd</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:00:00.000Z</news:publication_date>
      <news:title>Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-third-quarter-2026-update</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T13:00:00.000Z</news:publication_date>
      <news:title>Chemomab Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/VBIO/valion-bio-dr-armand-balboni-advisor-entolimod-data-readout</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:45:00.000Z</news:publication_date>
      <news:title>Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BHVN/biohaven-bhv-1530-clinical-activity-ena-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:39:12.664Z</news:publication_date>
      <news:title>Biohaven&apos;s Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CMND/clearmind-medicine-ptsd-patent-hong-kong</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:32:00.000Z</news:publication_date>
      <news:title>Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application Publication</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/STEX/streamex-monetary-metals-gold-yield-iras</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:30:27.000Z</news:publication_date>
      <news:title>Streamex Corp. and Monetary Metals &amp; Co. Expand Partnership to Unlock Gold Yield in IRAs</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-qtorin-docetaxel-empd</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:30:13.000Z</news:publication_date>
      <news:title>Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget’s Disease (EMPD)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ZTS/zoetis-usda-license-poulvac-procerta-vaccine</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:30:00.000Z</news:publication_date>
      <news:title>Zoetis Receives USDA License for Poulvac® Procerta® HVT-ND-ILT Vaccine for Chickens</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/USPH/us-physical-therapy-southwest-ideas-conference</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:30:00.000Z</news:publication_date>
      <news:title>U.S. Physical Therapy Presented at the 18th Annual Southwest IDEAS Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MDCX/medicus-pharma-regains-compliance-nasdaq-minimum-equity-requirement-continued-listing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:30:00.000Z</news:publication_date>
      <news:title>Medicus Pharma Regains Compliance with Nasdaq Minimum Equity Requirement for Continued Listing</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GSK/velzatinib-odd-japan-gist</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:25:35.000Z</news:publication_date>
      <news:title>Velzatinib granted Orphan Drug Designation (ODD) in Japan in GIST</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PASG/remix-therapeutics-rem-422-phase-1-data-eortc-nci-aacr</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:15:58.000Z</news:publication_date>
      <news:title>Remix Therapeutics Announces Updated Positive REM-422 Phase 1 Data in Adenoid Cystic Carcinoma at 2026 EORTC-NCI-AACR Symposium</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GNPX/genprex-trop2-predictive-biomarker-reqorsa-lung-cancer</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:12:19.262Z</news:publication_date>
      <news:title>Genprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung Cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CVS/aetna-for-you-baby-initiative-2032</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Aetna Commits to Connecting 90% of Members to Essential, End-to-End Maternal and Infant Care by 2032 with Launch of the Aetna For You &amp; Baby Initiative</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SER/enable-injections-arespo-partnership-aatd</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Enable Injections and ARespo Biopharma Announce Strategic Partnership</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/KPRX/kiora-kio-401-late-stage-therapeutics</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>How KIO-401 Positions Kiora as a Late-Stage Retinal Therapeutics Company</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NVCR/novocure-announces-upcoming-investor-events</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Novocure Announces Upcoming Investor Events</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALNY/alnylam-regeneron-fda-approval-livsayis-cemdisiran</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Alnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam&apos;s RNAi Platform in Less Than Nine Years</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EVGN/evogene-financial-results-q3-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/REGN/regeneron-new-data-ash-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ATYR/atyr2810-preclinical-data-ctos-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/KRRO/korro-participate-upcoming-investor-conferences-20261119</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Korro to Participate in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ADAG/adagene-phase-1-study-adg138-dosing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EVAX/evaxion-strategy-update-q3-2026-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Evaxion announces strategy and business update and third quarter 2026 financial results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MRKR/marker-therapeutics-cprit-grant-mt-601-phase-2</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-investor-conferences-december-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Axsome Therapeutics to Participate in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-annual-report-filing-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IRD/opus-genetics-phase-1-2-trial-opgx-rdh12</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T12:00:00.000Z</news:publication_date>
      <news:title>Opus Genetics Announces First Participant Dosed in Phase 1/2 Clinical Trial of OPGx-RDH12 Gene Therapy for Rare Inherited Childhood Blindness</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-ash-2026-blood-cancers</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T11:59:00.000Z</news:publication_date>
      <news:title>Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-investor-conference-december-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T11:55:00.000Z</news:publication_date>
      <news:title>ANI Pharmaceuticals to Present at Upcoming December Investor Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CDT/cdt-sarborg-sale-cryptocurrency-agent</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T11:45:00.000Z</news:publication_date>
      <news:title>CDT Notes Sarborg’s Sale of Cryptocurrency Trading Agent</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MRK/merck-isomorphic-labs-research-collaboration</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T11:45:00.000Z</news:publication_date>
      <news:title>Merck and Isomorphic Labs Enter Strategic Research Collaboration</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CMPS/compass-pathways-evercore-healthcare-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T11:30:00.000Z</news:publication_date>
      <news:title>Compass Pathways to Participate in 9th Annual Evercore Healthcare Conference on December 1</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HIT/health-in-tech-expands-distribution-tpa-100k-employees</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T11:30:00.000Z</news:publication_date>
      <news:title>Health In Tech Expands National Distribution Through TPA Serving More Than 100,000 Employees</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BDX/bd-time-2027-top-manufacturers</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T11:00:00.000Z</news:publication_date>
      <news:title>BD Named to TIME&apos;s 2027 List of America&apos;s Top Manufacturers</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ZYME/zymeworks-announces-participation-upcoming-investor-conferences-20261119</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T11:00:00.000Z</news:publication_date>
      <news:title>Zymeworks Announces Participation in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HCM/hutchmed-nmpa-approval-sovleplenib-itp-waiha</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T10:00:00.000Z</news:publication_date>
      <news:title>HUTCHMED Announces China NMPA Approval of SYVIK® (sovleplenib) for the Treatment of Primary Immune Thrombocytopenia and Warm Antibody Autoimmune Hemolytic Anemia</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SNY/jacobs-sanofi-insulin-manufacturing-germany</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T08:30:00.000Z</news:publication_date>
      <news:title>Jacobs selected by Sanofi to deliver new insulin manufacturing facility in Germany</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DXCM/dexcom-athenry-opening-commercial-production-milestone</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T07:30:00.000Z</news:publication_date>
      <news:title>Dexcom Marks Athenry Opening With Celebration of Commercial Production Milestone</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EVO/evotec-bristol-myers-squibb-second-ind-acceptance</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T07:06:00.000Z</news:publication_date>
      <news:title>Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ABBV/disco-abbvie-collaboration-bispecific-therapeutics</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T07:00:00.000Z</news:publication_date>
      <news:title>DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NVS/novartis-sales-cagr-growth-2031</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T06:00:00.000Z</news:publication_date>
      <news:title>Novartis projects +5% cc¹ sales CAGR through 2031 and sustained mid-single-digit growth over the long term</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SNY/sanofi-vaxrabeo-eu-approval-rabies-vaccine</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T06:00:00.000Z</news:publication_date>
      <news:title>Press Release: Sanofi’s next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SBC/sbc-medical-group-cybersecurity-incidents-japan</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T04:39:00.000Z</news:publication_date>
      <news:title>SBC Medical Group Reports Cybersecurity Incidents in Japan</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-announces-pricing-150-0-million-underwritten-public</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T02:59:00.000Z</news:publication_date>
      <news:title>SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EMMA/emmaus-life-sciences-quarterly-financial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T01:05:00.000Z</news:publication_date>
      <news:title>Emmaus Life Sciences Reports Quarterly Financial Results</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IMMP/immutep-eftisarc-neo-phase-ii-trial-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:12:00.000Z</news:publication_date>
      <news:title>Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/DRIO/dario-webmd-partnership-multi-condition-platform</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00.000Z</news:publication_date>
      <news:title>Dario and WebMD Health Services Announce Strategic Partnership to Deliver Dario&apos;s Multi-Condition Platform to Millions of Covered Lives</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LUCY/lucyd-armor-smart-safety-glasses-certified-australia-new-zealand</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00.000Z</news:publication_date>
      <news:title>Innovative Eyewear&apos;s Lucyd Armor® Smart Safety Glasses Now Certified for Australia and New Zealand</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/EHTH/medicare-enrollment-report-ai-tools-2027-plans</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00.000Z</news:publication_date>
      <news:title>Medicare Annual Enrollment Halftime Report: 75% of enrollees have used AI tools to review 2027 Medicare plans</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ELAN/elanco-share-repurchase-authorization-600-million</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00.000Z</news:publication_date>
      <news:title>Elanco Announces Inaugural $600 Million Share Repurchase Authorization</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HCM/hutchmed-hmpl-a830-preclinical-data-eortc-nci-aacr</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00.000Z</news:publication_date>
      <news:title>HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/REGN/livsayis-fda-approval-gmg-treatment</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T23:03:00.000Z</news:publication_date>
      <news:title>Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/OSCR/hy-vee-health-oscar-expansion-iowa-kansas-city-omaha</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T23:03:00.000Z</news:publication_date>
      <news:title>Hy-Vee Health with Oscar Expands Across Iowa, Into Kansas City and Omaha for 2027 Open Enrollment</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-micvo-phase-1-data-webcast</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T23:01:00.000Z</news:publication_date>
      <news:title>Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-nasdaq-listing-rule-5635-c-4-20261118</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T22:41:00.000Z</news:publication_date>
      <news:title>Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/SNY/infilbray-approved-first-treatment-type-3-gaucher-disease</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T22:19:00.000Z</news:publication_date>
      <news:title>Press Release: Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/HYFT/mindwalk-2026-agm-results</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T22:01:00.000Z</news:publication_date>
      <news:title>MindWalk Announces Results of 2026 Annual General Meeting of Shareholders</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TEVA/teva-rd-leadership-transition-eric-hughes-departure</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T22:00:00.000Z</news:publication_date>
      <news:title>Teva Announces R&amp;D Leadership Transition; Eric Hughes to Depart the Company</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-webcast-qtorin-program</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T22:00:00.000Z</news:publication_date>
      <news:title>Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ Program</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MRM/medirom-nasdaq-delisting-notice-annual-report-filing</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:45:00.000Z</news:publication_date>
      <news:title>MEDIROM Announces Receipt of Nasdaq Delisting Notice, Filing of Annual Report and Submission of Hearing Request</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/NSPR/inspiremd-first-us-commercial-tcar-procedures</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:30:00.000Z</news:publication_date>
      <news:title>InspireMD Announces First U.S. Commercial TCAR Procedures Using the FDA-Approved CGuard® Prime TransCarotid Stent System</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-participate-upcoming-investor-conferences-20261118</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:30:00.000Z</news:publication_date>
      <news:title>Cytek Biosciences to Participate in Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/UHS/universal-health-services-dividend-announcement</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:20:29.000Z</news:publication_date>
      <news:title>Universal Health Services, Inc. Announces Dividend</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/A/agilent-announces-cash-dividend-26-25-cents-per-share</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:15:00.000Z</news:publication_date>
      <news:title>Agilent Announces Cash Dividend of 26.25 Cents per Share</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ARDT/ardent-health-eight-facilities-a-hospital-safety-grade</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:15:00.000Z</news:publication_date>
      <news:title>Eight Ardent Health Facilities Earn ‘A’ Hospital Safety Grades from The Leapfrog Group for Fall 2026 Grading Period</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-inducement-grants-nasdaq-5635c4</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:15:00.000Z</news:publication_date>
      <news:title>Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PROK/prokidney-names-farah-ali-cmo</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:15:00.000Z</news:publication_date>
      <news:title>ProKidney Names Farah Ali, M.D., M.S., Chief Medical Officer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LUNG/pulmonx-piper-sandler-healthcare-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:05:31.000Z</news:publication_date>
      <news:title>Pulmonx to Participate in the Piper Sandler 38th Annual Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TCMD/tactile-medical-piper-sandler-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:05:00.000Z</news:publication_date>
      <news:title>Tactile Medical to Participate in the Piper Sandler 38th Annual Healthcare Conference</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ELOX/elox-phase-2a-exaluren-data-alport-syndrome</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:05:00.000Z</news:publication_date>
      <news:title>Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-investor-conferences-december-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:05:00.000Z</news:publication_date>
      <news:title>Arcus Biosciences to Participate in Two Upcoming Investor Conferences</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-piper-sandler-conference-2026</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:05:00.000Z</news:publication_date>
      <news:title>PROCEPT BioRobotics® to Participate in the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GERN/geron-corporation-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261118</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:05:00.000Z</news:publication_date>
      <news:title>Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/BLLN/billiontoone-responds-short-seller-report</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:05:00.000Z</news:publication_date>
      <news:title>BillionToOne Responds to Inaccurate and Misleading Short Seller Report</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/INNV/innovage-holding-corp-settlement-doj</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:05:00.000Z</news:publication_date>
      <news:title>InnovAge Holding Corp. Resolves Civil Matter with U.S. Department of Justice &amp; Participating States</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-inducement-awards-nasdaq-mdgl</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:04:00.000Z</news:publication_date>
      <news:title>Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/IMCC/im-cannabis-share-consolidation-nasdaq-compliance</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:01:00.000Z</news:publication_date>
      <news:title>IM Cannabis Announces Intention to Complete 3:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ALGN/align-technology-board-appointments</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:01:00.000Z</news:publication_date>
      <news:title>Paul J. Clancy and Ian Bell to Join Align Technology Board of Directors</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/LKFT/lakefront-new-subscription-right-plan</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T21:01:00.000Z</news:publication_date>
      <news:title>Lakefront Creates New Subscription Right Plan</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/GMAB/genmab-restricted-stock-units-warrants-employees</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T19:40:00.000Z</news:publication_date>
      <news:title>Grant of Restricted Stock Units and Warrants to Employees in Genmab</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/TVGN/tevogen-significant-liability-reduction-insider-control</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T19:30:00.000Z</news:publication_date>
      <news:title>Tevogen Highlights Significant Liability Reduction and Continued Insider Control</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MOH/molina-healthcare-illinois-commitment-expansion-access-care</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T17:45:00.000Z</news:publication_date>
      <news:title>Molina Healthcare of Illinois Commits $2.4 Million to Expand Access to Care Across the State</news:title>
    </news:news>
  </url>
</urlset>